BACKGROUND: Numerous acute reperfusion therapies (RPT) are currently investigated as potential new therapeutic targets in acute ischemic stroke (AIS). We conducted a comprehensive benefit-risk analysis of available clinical studies assessing different acute RPT, and investigated the utility of each intervention in comparison to standard intravenous thrombolysis (IVT) and in relation to the onset-to-treatment time (OTT). METHODS: A comprehensive literature search was conducted to identify all available published, peer-reviewed clinical studies that evaluated the efficacy of different RPT in AIS. Benefit-to-risk ratio (BRR), adjusted for baseline stroke severity, was estimated as the percentage of patients achieving favorable functional outcome (BRR1, mRS score: 0-1) or functional independence (BRR2, mRS score: 0-2) at 3 months divided by the percentage of patients who died during the same period. RESULTS: A total of 18 randomized (n = 13) and nonrandomized (n = 5) clinical studies fulfilled our inclusion criteria. IV therapy with tenecteplase (TNK) was found to have the highest BRRs (BRR1 = 5.76 and BRR2 = 6.82 for low-dose TNK; BRR1 = 5.80 and BRR2 = 6.87 for high-dose TNK), followed by sonothrombolysis (BRR1 = 2.75 and BRR2 = 3.38), while endovascular thrombectomy with MERCI retriever was found to have the lowest BRRs (BRR1 range, 0.31-0.65; BRR2 range, 0.52-1.18). A second degree negative polynomial correlation was detected between favorable functional outcome and OTT (R (2) value: 0.6419; P < 0.00001) indicating the time dependency of clinical efficacy of all reperfusion therapies. CONCLUSION: Intravenous thrombolysis (IVT) with TNK and sonothrombolysis have the higher BRR among investigational reperfusion therapies. The combination of sonothrombolysis with IV administration of TNK appears a potentially promising therapeutic option deserving further investigation.

Cerevast Therapeutics Inc Redmond Washington

Department of Neurology University Clinic at Erlangen Erlangen Germany

Department of Neurology University of Ioannina Ioannina Greece

Department of Neurology University of Tennessee Health Science Center Memphis Tennessee

Department of Neurology University of Tennessee Health Science Center Memphis Tennessee ; 2nd Department of Neurology Attikon Hospital School of Medicine University of Athens Athens Greece ; International Clinical Research Center St Anne's University Hospital in Brno Brno Czech Republic

Department of Neurology University of Texas Houston Medical School Houston Texas

Departments of Neurology and Neurogeriatry Johannes Wesling Clinic Minden Minden Germany

Neurovascular Unit Department of Neurology Hospital Vall d'Hebron Barcelona Spain

Zobrazit více v PubMed

Alexandrov AV. Current and future recanalization strategies for acute ischemic stroke. J. Intern. Med. 2010;267:209–219. PubMed

Alexandrov AV, Barlinn K. Taboos and opportunities in sonothrombolysis for stroke. Int. J. Hyperthermia. 2012;28:397–404. PubMed

Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 2004;351:2170–2178. PubMed

Balami JS, Chen R, Sutherland BA, Buchan AM. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future. CNS Neurol. Disord. Drug Targets. 2013;12:145–154. PubMed

Barlinn K, Alexandrov AV. Sonothrombolysis in ischemic stroke. Curr. Treat Options Neurol. 2013;15:91–103. PubMed

Barreto AD, Alexandrov AV. Adjunctive and alternative approaches to current reperfusion therapy. Stroke. 2012;43:591–598. PubMed PMC

Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J. Neurol. 2014;261:1069–1072. PubMed

Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J. Stroke. 2013;15:90–98. PubMed PMC

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N. Engl. J. Med. 2013;368:893–903. PubMed PMC

Ciccone A, Valvassori L, Ponzio M, Ballabio E, Gasparotti R, Sessa M, et al. Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv. Surg. 2010;2:74–79. PubMed

Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. N. Engl. J. Med. 2013;368:904–913. PubMed PMC

Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Saf. 1996;15:1–7. PubMed

Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:227–276. PubMed

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003–2011. PubMed

Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health. 2010;13:657–666. PubMed

Hennerici MG, Kern R, Szabo K. Non-pharmacological strategies for the treatment of acute ischaemic stroke. Lancet Neurol. 2013;12:572–584. PubMed

Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, et al. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014;13:567–574. PubMed PMC

Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N. Engl. J. Med. 2013;368:914–923. PubMed PMC

Landry A, Foran M, Koyfman A. In patients with acute ischemic stroke, do different thrombolytic doses, agents, or routes of administration lead to different outcomes? Ann. Emerg. Med. 2014;63:435–436. PubMed

Lapchak PA, Kikuchi K, Butte P, Holscher T. Development of transcranial sonothrombolysis as an alternative stroke therapy: incremental scientific advances toward overcoming substantial barriers. Expert Rev. Med. Devices. 2013;10:201–213. PubMed

Martinez-Sanchez P, Diez-Tejedor E, Fuentes B, Ortega-Casarrubios MA, Hacke W. Systemic reperfusion therapy in acute ischemic stroke. Cerebrovasc. Dis. 2007;24(Suppl 1):143–152. PubMed

Muir KW, Weir CJ, Murray GD, Povey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27:1817–1820. PubMed

Naylor AR. Time is brain! Surgeon. 2007;5:23–30. PubMed

Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380:1231–1240. PubMed PMC

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N. Engl. J. Med. 2012;366:1099–1107. PubMed

PENUBRA Pivotal Stroke Trial. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40:2761–2768. PubMed

Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, Cenciarelli S, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 2012;10:CD008348. PubMed

Rother J, Ford GA, Thijs VN. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc. Dis. 2013;35:313–319. PubMed

Rubiera M, Alexandrov AV. Sonothrombolysis in the management of acute ischemic stroke. Am. J. Cardiovasc. Drugs. 2010;10:5–10. PubMed

San Roman L, Obach V, Blasco J, Macho J, Lopez A, Urra X, et al. Single-center experience of cerebral artery thrombectomy using the TREVO device in 60 patients with acute ischemic stroke. Stroke. 2012;43:1657–1659. PubMed

Saqqur M, Tsivgoulis G, Nicoli F, Skoloudik D, Sharma VK, Larrue V, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J. Neuroimaging. 2014;24:209–220. PubMed

Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380:1241–1249. PubMed

Shi ZS, Liebeskind DS, Xiang B, Ge SG, Feng L, Albers GW, et al. Predictors of functional dependence despite successful revascularization in large-vessel occlusion strokes. Stroke. 2014;45:1977–1984. PubMed PMC

Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432–1438. PubMed

Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39:1205–1212. PubMed

Tarr R, Hsu D, Kulcsar Z, Bonvin C, Rufenacht D, Alfke K, et al. The POST trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J. Neurointerv. Surg. 2010;2:341–344. PubMed

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 1995;333:1581–1587. PubMed

Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke. 2010;41:280–287. PubMed

Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst. Rev. 2013;5:CD000514. PubMed PMC

del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4–11. PubMed

Reperfusion therapies of acute ischemic stroke: potentials and failures